- UroToday Home
- Urologic Oncology
The Latest Research on CRPC with Bone Metastases
Recent Abstracts
-
Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures.CRPC w/ bone metastasesAugust 13, 2025
-
Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies.CRPC w/ bone metastasesJune 30, 2025
-
The Tight Relationship Between the Tumoral Microenvironment and Radium-223.CRPC w/ bone metastasesFebruary 27, 2025
-
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.CRPC w/ bone metastasesJanuary 21, 2025
-
Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compareCRPC w/ bone metastasesNovember 22, 2024
-
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.CRPC w/ bone metastasesMay 22, 2024
-
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.CRPC w/ bone metastasesFebruary 16, 2024
-
BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System.CRPC w/ bone metastasesOctober 30, 2023
-
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.CRPC w/ bone metastasesOctober 26, 2023
-
Radium-223 in metastatic castration resistant prostate cancer: whole body diffusion-weighted MRI to assess response.CRPC w/ bone metastasesOctober 9, 2023
Beyond the Abstracts
-
Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies - Beyond the AbstractCRPC w/ bone metastasesAugust 13, 2025
-
Bone Targeted Therapy and Skeletal Related Events in the Era of Enzalutamide and Abiraterone Acetate for Castration Resistant Prostate Cancer with Bone Metastases - Beyond the AbstractCRPC w/ bone metastasesOctober 27, 2020
-
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT: Beyond the AbstractCRPC w/ bone metastasesApril 7, 2017
-
Prostate Cancer Cure is Possible: Beyond the AbstractCRPC w/ bone metastasesJanuary 5, 2017
-
The use of radium 223 dichloride in a multidisciplinary approach for treating metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Elisa BorsòCRPC w/ bone metastasesFebruary 11, 2015